Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer

被引：0
|
作者：
Gaulin, J. [1 ]
Kotb, R. [1 ]
Turcotte, E. [2 ]
Berard, G. [3 ]
Sawan, B. [4 ]
Schmutz, G. [5 ]
Beauregard, P. [1 ]
机构：
[1] CHU Sherbrooke, Dept Hematol & Oncol, Sherbrooke, PQ J1H 5N4, Canada
[2] CHU Sherbrooke, Dept Nucl Med, Sherbrooke, PQ J1H 5N4, Canada
[3] CHU Sherbrooke, Dept Clin Pharm, Sherbrooke, PQ J1H 5N4, Canada
[4] CHU Sherbrooke, Dept Pathol, Sherbrooke, PQ J1H 5N4, Canada
[5] CHU Sherbrooke, Dept Radiol, Sherbrooke, PQ J1H 5N4, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷 / 05期
关键词：
Colorectal cancer; bevacizumab; third-line therapy; FLUOROURACIL FAILURE; RANDOMIZED-TRIAL; PLUS IRINOTECAN; OXALIPLATIN; LEUCOVORIN; CETUXIMAB; COMBINATION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bevacizumab is Currently approved in association with first- and second-line 5-fluorouracil-based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness Of bevacizumab in third-line settings are available. We describe a patient refractory to FOLFIRI and FOLFOX chemotherapy regimens who showed a dramatic and durable response to bevacizumab and FOLFIRI. We also review and discuss the available literature.
引用
收藏
页码：331 / 333
页数：3
相关论文
共 50 条
  • [21] A real-world study: Efficacy of the third-line therapy of standard therapy versus rechallenge-chemotherapy in refractory metastatic colorectal cancer
    Xu, X.
    Fu, J.
    Xu, H.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S49 - S49
  • [22] Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience
    Ozkan, Merve
    Oflazoglu, Utku
    Yildiz, Yasar
    Guc, Zeynep G.
    Salman, Tarik
    Unal, Sinan
    Kucukzeybek, Yuksel
    Alacacioglu, Ahmet
    [J]. MEDICINE, 2023, 102 (50) : E36435
  • [23] Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    Chong, G
    Dickson, JLB
    Cunningham, D
    Norman, AR
    Rao, S
    Hill, ME
    Price, TJ
    Oates, J
    Tebbutt, N
    [J]. BRITISH JOURNAL OF CANCER, 2005, 93 (05) : 510 - 514
  • [24] COST EFFECTIVENESS OF FRUQUINTINIB VERSUS REGORAFENIB AS THE THIRD-LINE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER IN CHINA
    Xin, G.
    Li, H. C.
    Peng, C.
    Wang, N.
    Ma, X.
    Xiong, X. M.
    Ma, A. X.
    [J]. VALUE IN HEALTH, 2019, 22 : S83 - S83
  • [25] Sequencing Third-Line Therapies for Metastatic Colorectal Cancer: A Guide for Determining Which Therapy to Use First
    Cusnir, Mike
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (05)
  • [26] Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    G Chong
    J L B Dickson
    D Cunningham
    A R Norman
    S Rao
    M E Hill
    T J Price
    J Oates
    N Tebbutt
    [J]. British Journal of Cancer, 2005, 93 : 510 - 514
  • [27] Efficacy and safety of nilotinib as third-line therapy in an elderly patient with CML
    Caocci, Giovanni
    Atzeni, Sandra
    La Nasa, Giorgio
    [J]. CLINICAL MANAGEMENT ISSUES, 2012, 6 : 15 - 18
  • [28] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    [J]. ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [29] A Decade of Progress: Advances in the Third-Line Treatment of Patients With Metastatic Colorectal Cancer
    Bekaii-Saab, Tanios
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (02): : S23 - S30
  • [30] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    [J]. CANCER SCIENCE, 2018, 109 : 601 - 601
12345